SCM
URGN icon

Silverarc Capital Management’s UroGen Pharma URGN Stock Holding History

Silverarc Capital Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.9M Sell
1,301,979
-201,066
-13% -$5.45M 4.98% 4
2026
Q1 		$27M Sell
1,503,045
-235,776
-14% -$4.73M 2.76% 13
2025
Q4 		$40.7M Buy
1,738,821
+161,538
+10% +$3.5M 5.66% 3
2025
Q3 		$31.5M Sell
1,577,283
-445,199
-22% -$7.99M 4.24% 5
2025
Q2 		$27.7M Buy
2,022,482
+641,324
+46% +$6.15M 5.11% 4
2025
Q1 		$15.3M Buy
1,381,158
+260,685
+23% +$2.78M 3.12% 10
2024
Q4 		$11.9M Buy
1,120,473
+219,344
+24% +$2.63M 2.61% 13
2024
Q3 		$11.4M Sell
901,129
-200,871
-18% -$2.98M 2.57% 12
2024
Q2 		$18.5M Buy
1,102,000
+593,413
+117% +$8.44M 4.36% 4
2024
Q1 		$7.63M Sell
508,587
-16,817
-3% -$275K 2.12% 16
2023
Q4 		$7.88M Buy
525,404
+16,521
+3% +$214K 2.35% 15
2023
Q3 		$7.13M Buy
+508,883
New +$8.17M 2.16% 13

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Silverarc Capital Management's URGN Position: Q2 2026 in Review

Silverarc Capital Management reduced its UroGen Pharma (URGN) stake by 13% in Q2 2026, selling an estimated $5.45M and leaving 1,301,979 shares worth $47.9M. The position accounts for 4.98% of the portfolio, ranked #4.

Silverarc Capital Management first reported a position in URGN in Q3 2023 and has held it in 12 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Silverarc Capital Management held 1,301,979 shares of UroGen Pharma worth $47.9M as of Q2 2026.
  • Silverarc Capital Management sold 201,066 UroGen Pharma shares in Q2 2026, an estimated $5.45M.
  • UroGen Pharma made up 4.98% of Silverarc Capital Management's portfolio in Q2 2026, its #4 holding.
  • Silverarc Capital Management first reported a position in UroGen Pharma in Q3 2023 and has held it in 12 quarters since.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.